[1] |
Albasri AM. Nasopharyngeal carcinoma metastasis to the breast[J]. Saudi Med J, 2020, 41(10): 1130-1134. DOI: 10.15537/smj.2020.10.25420.
pmid: 33026055
|
[2] |
Özşen M, Tolunay S, Polatkan SAV, et al. Metastatic neoplasms to the breast[J]. Int J Surg Pathol, 2023: 10668969231201415. DOI: 10.1177/10668969231201415.
|
[3] |
Lee SH, Park JM, Kook SH, et al. Metastatic tumors to the breast: mammographic and ultrasonographic findings[J]. J Ultrasound Med, 2000, 19(4): 257-262. DOI: 10.7863/jum.2000.19.4.257.
pmid: 10759349
|
[4] |
Wan X, Zhang HQ, Zhang YH, et al. Metastases to the breast from extramammary nonhematological malignancies: case series[J]. Int J Gen Med, 2020, 13: 1105-1114. DOI: 10.2147/ijgm.s276602.
pmid: 33209053
|
[5] |
Semba R, Horimoto Y, Arakawa A, et al. Metastatic breast tumors from extramammary malignancies: a case series[J]. Surg Case Rep, 2021, 7(1): 154. DOI: 10.1186/s40792-021-01235-2.
pmid: 34185204
|
[6] |
Zhou P, Chang NN, Abraham SC, et al. Metastatic nonhemato-poietic neoplasms to the breast: a study of 238 cases[J]. Hum Pathol, 2022, 125: 59-67. DOI: 10.1016/j.humpath.2022.04.009.
|
[7] |
Hassanipour S, Delam H, Arab-Zozani M, et al. Survival rate of prostate cancer in Asian countries: a systematic review and meta-analysis[J]. Ann Glob Health, 2020, 86(1): 2. DOI: 10.5334/aogh.2607.
pmid: 31976303
|
[8] |
Gandaglia G, Abdollah F, Schiffmann J, et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis[J]. Prostate, 2014, 74(2): 210-216. DOI: 10.1002/pros.22742.
pmid: 24132735
|
[9] |
Lee UJ, Jones JS. Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening[J]. Prostate Cancer Prostatic Dis, 2009, 12(1): 52-56. DOI: 10.1038/pcan.2008.26.
|
[10] |
Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores[J]. J Clin Oncol, 2017, 35(20): 2240-2250. DOI: 10.1200/jco.2016.69.4935.
pmid: 28448241
|
[11] |
Karlsson CT, Malmer B, Wiklund F, et al. Breast cancer as a second primary in patients with prostate cancer—estrogen treatment or association with family history of cancer?[J]. J Urol, 2006, 176(2): 538-543. DOI: 10.1016/j.juro.2006.03.036.
|
[12] |
Thellenberg C, Malmer B, Tavelin B, et al. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer[J]. J Urol, 2003, 169(4): 1345-1348. DOI: 10.1097/01.ju.0000056706.88960.7c.
pmid: 12629357
|
[13] |
Capper CP, Rae JM, Auchus RJ. The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer[J]. Horm Cancer, 2016, 7(3): 149-164. DOI: 10.1007/s12672-016-0259-0.
|
[14] |
Bonacho T, Rodrigues F, Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review[J]. Biotech Histochem, 2020, 95(2): 71-91. DOI: 10.1080/10520295.2019.1651901.
pmid: 31502889
|
[15] |
Lee AHS, Hodi Z, Soomro I, et al. Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies[J]. Histopathology, 2020, 77(2): 303-313. DOI: 10.1111/his.14141.
|
[16] |
Fentiman IS. The biology of male breast cancer[J]. Breast, 2018, 38: 132-135. DOI: 10.1016/j.breast.2018.01.001.
pmid: 29316513
|
[17] |
Kristiansen I, Stephan C, Jung K, et al. Sensitivity of HOXB13 as a diagnostic immunohistochemical marker of prostatic origin in prostate cancer metastases: comparison to PSA, prostein, androgen receptor, ERG, NKX3.1, PSAP, and PSMA[J]. Int J Mol Sci, 2017, 18(6): 1151. DOI: 10.3390/ijms18061151.
|
[18] |
Cheng CW, Chan LW, Ng CF, et al. Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen[J]. Int J Urol, 2006, 13(4): 463-465. DOI: 10.1111/j.1442-2042.2006.01327.x.
|
[19] |
Habacha B, Bundschuh RA, Gärtner FC, et al. Case report: breast metastasis in a prostate cancer patient[J]. Nuklearmedizin, 2021, 60(4): 302-303. DOI: 10.1055/a-1310-3633.
pmid: 33738785
|
[20] |
Lima V, Martinez-Lapus FG, Demegillo KJ. Breast metastasis from castrate-resistant prostatic adenocarcinoma mimicking as a second primary: a case report[J]. World J Oncol, 2020, 11(1): 37-40. DOI: 10.14740/wjon1258.
pmid: 32095188
|